TickerTalks
Browse all tickers →
TickerTalks›$NVO
NVNVO

Novo Nordisk A/S

$NVO·$172B·Drug Manufacturers - General·Healthcare
$38.72-1.3%YTD-26.3%1Y-30.9%
Price updated 10m ago·X counts updated 5d ago
NVNVO
$NVONovo Nordisk A/S
$38.72-1.29%832 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $NVO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

832X posts · last 7 days
Sep 28Oct 11
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $NVO's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 60% of tracked names.

Mixed sentimentAI analysisGenerated by AI from underlying data23 posts analyzed · as of 2026-10-02

Sentiment is split as the Wegovy oral pill launches in Denmark tomorrow and EASD 2026 opens — Novo bulls call this a reset moment with Wegovy HD at a fresh TRx high and the fastest-selling drug ever on the roster. Bears quote Lilly's CEO saying 70% of 700,000 Medicare GLP-1 starts went to Lilly plus a 30%+ oral share tied to a 30-day-free sampling program. The stock dropped 10.3% on the week, which both sides use to argue their case.

Read what X is saying about $NVO

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NVO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Comeback attemptSelling offAI verdict · as of 2026-10-03

Falling on heavy selling — points lower unless it turns around.

The Ozempic franchise got cut in half as Lilly took US obesity share — now priced for continued deterioration while inflection signals start showing.

Novo Nordisk owns Ozempic and Wegovy — the GLP-1 franchise that redefined diabetes and obesity. The stock has been roughly halved in a year as Lilly ran away with the US obesity narrative, and Novo is now hunting for its answer.

  • The business is quietly re-accelerating: Q1 2026 revenue grew 24% YoY to $96.8B after Q4's -7.6% YoY — the trough looks behind, with Wegovy HD at fresh prescription highs and ~$4B of M&A deals rebuilding the pipeline around amylin.
  • The valuation already discounts the share loss: 10x TTM earnings and ~3.8x sales on 45% operating margins and 32% ROIC is cheap for a franchise still growing low-double-digits.
  • The counter is the Lilly scoreboard: Lilly cited 70% of 700,000 Medicare GLP-1 starts going to them, so Novo's growth is coming from oral conversion and ex-US, not US obesity share recovery.

A strong Nov 4 print plus EASD data moves it off the floor; another Lilly-dominated US quarter and it drifts lower.

Agrees with X sentimentX is split and reasonably so — the bull case on Wegovy HD TRx highs and the Danish oral Wegovy launch is real; the bear case citing Lilly's 70% share of 700K Medicare GLP-1 starts is also real. Novo is still growing and already priced for the share loss, which is where the mild bullish lean comes from.

What to watch: Nov 4 Q3 earnings — specifically oral Wegovy launch metrics (Denmark velocity, EU/US rollout dates), US obesity-share stabilization vs Lilly, and any EASD 2026 amylin data. A clean oral ramp moves it off the floor; a quiet quarter extends the breakdown.

On the calendar: 2026-11-04 — Q3 2026 earnings

Read the AI verdict on $NVO

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes GLP-1 drugs Ozempic and Wegovy for diabetes and obesity with semaglutide driving blockbuster revenue growth.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $NVO.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $NVO

Neutral — Makes GLP-1 drugs Ozempic and Wegovy for diabetes and obesity with semaglutide driving blockbuster revenue growth.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
10.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
32.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
45.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
3.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
66.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
81.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.96$0.82+17.1%
Q1 2026May 6, 2026$1.04$0.87+19.5%
Q4 2025Feb 3, 2026$1.00$0.90+11.1%
Q3 2025Nov 5, 2025$1.02$0.77+32.5%
Next earningsWed, Nov 4·consensus EPS $0.74

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$96.8B+24.0%86.0%61.6%$10.93$12.0B
Q4 FY25$79.1B-7.6%80.9%40.1%$6.06$-36.2B
Q3 FY25$75.0B+5.1%76.1%31.6%$4.50$30.7B
Q2 FY25$76.9B+12.9%83.3%43.5%$5.96$24.5B

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$302.3B$296.4B – $312.2B$22.30$20.73 – $25.3216
FY27$306.3B$302.6B – $311.5B$21.98$20.31 – $23.1416
FY28$324.6B$303.1B – $361.3B$23.91$21.85 – $27.4213
FY29$350.3B$327.1B – $389.9B$27.38$25.02 – $31.4014
FY30$363.5B$339.4B – $404.6B$28.33$25.89 – $32.4914

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.14%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-8.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-13.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 3.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.355-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 40 other (36 6-Ks · 2 11-Ks · 1 13G · 1 SD) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Why Novo Nordisk (NVO) Dipped More Than Broader Market Todayzacks.com·3d agoAbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?fool.com·3d agoNovo Down 11% in a Month: How Should Investors Approach the Stock Now?zacks.com·4d agoBristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?fool.com·6d agoUBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.fool.com·8d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$PFE$JNJ$ABBV$MRK$BMY$AMGN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport